Last reviewed · How we verify
hand mixed tobramycin
hand mixed tobramycin is a Aminoglycoside antibiotic Small molecule drug developed by Washington University School of Medicine. It is currently FDA-approved for Serious gram-negative bacterial infections, Cystic fibrosis-associated Pseudomonas aeruginosa lung infections (inhaled formulation). Also known as: Tobramycin.
Tobramycin is an aminoglycoside antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit.
Tobramycin is a small molecule that inhibits the 70S ribosome, classified as an inhibitor. It has been studied in the context of total knee replacement, where it was administered in hand-mixed and pre-mixed forms.
At a glance
| Generic name | hand mixed tobramycin |
|---|---|
| Also known as | Tobramycin |
| Sponsor | Washington University School of Medicine |
| Drug class | Aminoglycoside antibiotic |
| Target | Bacterial 30S ribosomal subunit |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Tobramycin binds irreversibly to the bacterial 30S ribosomal subunit, disrupting the reading of mRNA codons and causing misincorporation of amino acids into proteins. This leads to production of non-functional proteins and ultimately bacterial cell death. It is bactericidal and effective against aerobic gram-negative bacteria and some gram-positive organisms.
Approved indications
- Serious gram-negative bacterial infections
- Cystic fibrosis-associated Pseudomonas aeruginosa lung infections (inhaled formulation)
Common side effects
- Nephrotoxicity
- Ototoxicity
- Neuromuscular blockade
- Injection site reactions
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- hand mixed tobramycin CI brief — competitive landscape report
- hand mixed tobramycin updates RSS · CI watch RSS
- Washington University School of Medicine portfolio CI
Frequently asked questions about hand mixed tobramycin
What is hand mixed tobramycin?
How does hand mixed tobramycin work?
What is hand mixed tobramycin used for?
Who makes hand mixed tobramycin?
Is hand mixed tobramycin also known as anything else?
What drug class is hand mixed tobramycin in?
What development phase is hand mixed tobramycin in?
What are the side effects of hand mixed tobramycin?
What does hand mixed tobramycin target?
Related
- Drug class: All Aminoglycoside antibiotic drugs
- Target: All drugs targeting Bacterial 30S ribosomal subunit
- Manufacturer: Washington University School of Medicine — full pipeline
- Therapeutic area: All drugs in Infectious Disease
- Indication: Drugs for Serious gram-negative bacterial infections
- Indication: Drugs for Cystic fibrosis-associated Pseudomonas aeruginosa lung infections (inhaled formulation)
- Also known as: Tobramycin
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing